EUVIMEDEUVIMED entdecken
Crossref

2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis

JUAN P. FRIAS

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2857-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JUAN P. FRIAS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Many individuals with T2D remain inadequately controlled despite treatment with GLP-1 receptor agonists (RA). Icovamenib is an orally administered investigational small molecule for diabetes. Icovamenib targets menin, a transcriptional regulator implicated in beta-cell dysfunction, that modulates pathways regulating insulin secretion. COVALENT-111 evaluated icovamenib in adults with inadequately controlled T2D. This analysis assessed glycemic outcomes in those receiving background GLP-1 RA therapy at baseline.

Methods

COVALENT-111 is a randomized, placebo-controlled study evaluating icovamenib in adults with T2D. Eligible participants had HbA1c 7.0-10.5% while receiving stable antihyperglycemic therapy. Participants continued baseline therapy and were randomly assigned to 100mg icovamenib or placebo once daily for 8-12 weeks. This subgroup analysis included participants receiving background GLP-1 RA therapy at baseline. The primary outcome was change in HbA1c. Safety was evaluated through adverse event monitoring.

Results

12 icovamenib- (age 53±9 yr, T2D duration 5.4±0.8 yr, HbA1c 8.4±0.9%, BMI 35.1±3.3 kg/m2, mean±SD) vs 4 placebo-treated (age 58±9 yr, T2D duration 4.8±2.6 yr, HbA1c 7.9±0.3%, BMI 32.5±3.5 kg/m2) patients. At Week 52, treatment with icovamenib resulted in mean HbA1c change of -1.2%, compared with +0.6% with placebo, corresponding to a placebo-adjusted reduction of 1.8% (p=0.05). C-peptide index improved relative to placebo. Icovamenib was generally well tolerated; no serious AEs or discontinuations. The safety profile in participants on background GLP-1 therapy was consistent with overall study population.

Conclusion

In adults with T2D receiving background GLP-1 RA therapy, icovamenib showed clinically meaningful reductions in HbA1c vs placebo, with the benefit continuing at 52 weeks. These findings suggest icovamenib may provide additive glycemic benefit alongside GLP-1-based therapy and support further evaluation of menin inhibition for T2D. Disclosure J.P. Frias: Employee; Ended; Biomea Fusion.

Zitieren

APA

FRIAS, J. P. (2026). 2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2857-lb

Vancouver

FRIAS JP. 2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2857-lb

BibTeX
@article{FRIAS2026,
  author = {FRIAS, JUAN P.},
  title = {2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2857-lb}
}
Kostenlos starten →